Mukul Agarwal’s Rs 450 Crore Investment: 6 Stocks to Watch

Super investor Mukul Agarwal, founder of Param Capital Group, has recently added six new stocks to his portfolio worth Rs 450 crore. These include companies in real estate, manufacturing, and healthcare, each showing varying levels of growth and potential. Here’s a detailed look at his new investments.

Mukul AgarwalParam Capital GroupIndian StocksInvestment StrategiesMarket AnalysisReal EstateJul 28, 2025

Mukul Agarwal’s Rs 450 Crore Investment: 6 Stocks to Watch

Real Estate:When it comes to naming the top super investors of India, Mukul Agarwal is a name that will probably always make it to the top few. Founder of Param Capital Group, Agarwal is widely known for his bold investment strategies, which almost always have a strong impact on the markets. He is often referred to as one of the Warren Buffetts of India.

Currently, Mukul Agarwal holds 64 stocks in his portfolio, all worth Rs 7,578 crore. However, what has caught the attention of investors across the board are the six fresh additions to his portfolio worth almost Rs 450 crore. Let us try and see if we can find out what is the reason behind his buying spree.

Valor Estate Ltd

Incorporated in 2007, Valor Estate, earlier known as DB Realty Limited, is engaged in the business of real estate construction, development, and other related activities. With a market cap of Rs 9,956 crore, most of the company’s projects are based in and around Mumbai and are under various stages of planning and construction. Mukul Agarwal just bought a 1.2% stake in the company worth Rs 120 crore.

The company’s sales saw a 46% compound growth from Rs 160 crore in FY20 to Rs 1,133 crore in FY25. EBITDA (earnings before interest, taxes, depreciation, and amortisation) was a negative Rs 235 crore for FY20, saw an operating profit after years in FY24 of Rs 150 crore, but was down to operating losses of Rs 97 crore in FY25. Net profit saw a rocky road in the last 5 years, with a string of losses:

| FY | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|----|------|------|------|------|------|------|
| Profits/Cr | -440 | -167 | 22 | -90 | 1,317 | -118 |

The share price of Valor Estate Ltd was around Rs 6 in July 2020, and as of the closing on 25th July 2025, it is at Rs 185, which is almost a 3,000% growth. The company’s share is trading at a negative PE due to consistent losses, but the industry median is around 38x currently. The 10-year median PE for the company is however 19x, while the industry median for the same period is 28x.

Wendt India Ltd

Wendt India is a leading manufacturer of Super Abrasives, Machining Tools, and Precision Components. It is a joint venture between 3M (via Wendt GmbH) and Carborundum Universal (Murugappa Group). Both the companies hold 37.5% shares in the company. With a market cap of Rs 1,934 crore, the company is a preferred supplier for many of the automobile, auto component, engineering, aerospace, defense, and ceramics customers for their Super Abrasive Tooling solutions, Grinding & Honing Machines, and Precision components.

Mukul Agarwal just bought a 2.5% stake in the company worth Rs 48.4 crore. The company’s sales grew from Rs 143 crore in FY20 to Rs 234 crore in FY25, which is a 10% compound growth. The EBITDA saw a compound growth of 23% from Rs 19 crore to Rs 53 crore in the same period. The net profits grew from Rs 10 crore in FY20 to Rs 39 crore in FY25, logging in a compound growth of 31% in 5 years. The share price of Wendt India Ltd was about Rs 2,565 in July 2020, and as of closing on 25th July 2025, it was at Rs 9,672, which is a jump of almost 280%. The company’s share is trading at a PE of 55x, which is closer to the industry median of 51x. The 10-year median PE for Wendt is 46x, while the industry median for the same period is just 36x.

Tatva Chintan Pharma Chem Ltd

Incorporated in 1996, Tatva Chintan Pharma Chem Ltd is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals. With a current market cap of Rs 2,680 crore, the company has a portfolio of 214 products divided into categories of Pharmaceuticals & Agrochemicals Intermediates, Structure Directing Agents (SDA), Phase Transfer Catalyst (PTC), and Electrolyte Salts & Others.

Mukul Agarwal just bought a 1.3% stake in the company worth Rs 34.4 crore. The company’s sales have grown at a compound rate of just 8% in the last 5 years from Rs 263 crore in FY20 to Rs 383 crore in FY25. The EBITDA, however, has seen a drop from Rs 55 crore in FY20 to Rs 34 crore in FY25. The net profits also dropped from Rs 38 crore in FY20 to Rs 6 crore in FY25. The share price of Tatva Chintan Pharma Chem Ltd was around Rs 2,265 when it was listed in July 2021. As of closing on 25th July 2025, the price was Rs 1,146, which is almost a 50% drop. The company’s share is currently trading at a PE of a huge 374, while the industry median is at 35x. The long-term median for the company is 76x, which is higher than the industry median for the same period, which is 28x.

Yatharth Hospital & Trauma Care Services Ltd

Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospital at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. With a market cap of Rs 6,040 crore, Yatharth Hospitals has the 8th and 10th largest private hospitals in the NCR, with 7 hospitals across North India with 87% of the beds in Metro. Mukul Agarwal just bought a 1.1% stake in the company worth Rs 69 crore.

The company’s sales have grown at a compound rate of just 45% in the last 5 years from Rs 136 crore in FY20 to Rs 880 crore in FY25. The EBITDA logged in a compound jump of about 42% in the same period from Rs 38 crore to Rs 220 crore. The company posted losses of Rs 2 crore in FY20 and then turned things around with logging in profits consistently and closing FY25 at profits of Rs 131 crore. The share price of Yatharth Hospital & Trauma Care Services Ltd was around Rs 330 at listing in August 2023, which has grown to Rs 627 as of closing on 25th July 2025, which is a 90% jump. The company’s share is trading at a current PE of 46x, and the industry median is around 69x.

Jammu and Kashmir Bank Ltd & Monolithisch India Ltd

Agarwal also bought a 1.3% stake in Jammu and Kashmir Bank Ltd worth Rs 153 crore and another 2.3% in Monolithisch India Ltd worth Rs 21 crore. To know more, read a detailed analysis into Jammu and Kashmir Bank Ltd and a deeper dive into Agarwal’s buy into Monolithisch India Ltd.

Big Moves – What Next?

Mukul Agarwal’s fresh buys have raised a lot of questions and rightly so. After all, he is not the average Joe when it comes to Indian markets. He is a mammoth that has proven his power and strength time and again. These six companies he has added to his portfolio for almost Rs 450 crore have a mix of companies showing a turnaround, companies still struggling with profits, and also companies that have shown some solid growth. The question is what is it that triggered this mixed bag of buys.

Now that is something that probably only Mukul Agarwal himself knows. However, it would not be wise to turn your eyes away from these stocks, given that they have managed to get Agarwal’s attention. Add to watchlist maybe?

Disclaimer

Note: We have relied on data from www.Screener.in and www.trendlyne.com throughout this article. Only in cases where the data was not available, have we used an alternate, but widely used and accepted source of information. The purpose of this article is only to share interesting charts, data points, and thought-provoking opinions. It is NOT a recommendation. If you wish to consider an investment, you are strongly advised to consult your advisor. This article is strictly for educative purposes only.

Frequently Asked Questions

Who is Mukul Agarwal?

Mukul Agarwal is a renowned super investor and founder of Param Capital Group, known for his bold and impactful investment strategies in the Indian markets.

What is the total value of Mukul Agarwal's portfolio?

Mukul Agarwal's current portfolio is worth Rs 7,578 crore, with recent additions totaling Rs 450 crore.

What are the six new stocks added to Mukul Agarwal's portfolio?

The six new stocks are Valor Estate Ltd, Wendt India Ltd, Tatva Chintan Pharma Chem Ltd, Yatharth Hospital & Trauma Care Services Ltd, Jammu and Kashmir Bank Ltd, and Monolithisch India Ltd.

Why are these new investments significant?

These investments are significant because they represent a mix of companies showing various levels of growth and potential, and they have caught the attention of a renowned investor like Mukul Agarwal.

What should investors do with this information?

Investors should consider adding these stocks to their watchlist, but they should also consult their financial advisor before making any investment decisions.